ICAM1 and neoplasm: We have proved that ICAM1-specific CAR-T cells were not able to kill SKBR3 cells in vitro and in vivo, indicating that ICAM1 would be an ideal tumor-associated antigen target for CAR-T cells to treat TNBC.